Mar 21 |
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
|
Feb 29 |
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
|
Feb 27 |
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
|
Feb 26 |
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
|
Feb 23 |
Theratechnologies Full Year 2023 Earnings: Misses Expectations
|
Feb 21 |
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
|
Feb 20 |
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
|
Feb 15 |
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
|
Feb 6 |
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
|
Jan 31 |
Positive Signs As Multiple Insiders Buy Theratechnologies Stock
|